Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...
Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback